Tolerance of ICI reintroduction
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | |
| Delay of resumption of ICI after meningitis (days) | 373 | 54 | 24 | 118 | 4 (No ICI discontinuation) | 126 | 19 |
| ICI regimen at the rechallenge | Ipilimumab 1 mg/kg +nivolumab 3 mg/kg | Ipilimumab 1 mg/kg +nivolumab 3 mg/kg | Spartalizumab 400 mg | Nivolumab 3 mg/kg | Nivolumab 3 mg/kg | Spartalizumab 400 mg +ribociclib 600 mg/day | Nivolumab 3 mg/kg |
| Steroid treatment at the time of ICI resumption* | 0.5 mg/kg/day | 0 | 0 | 0 | 0 | 0 | 0 |
| Meningitis recurrence | No | No | No | No | No | No | No |
| Other irAEs occurrence at rechallenge with ICIs | No | No | Interstitial lung disease (grade 3) | No | No | No | No |
| Cancer status at 3 months from rechallenge with ICIs | PD | PR | PD | PD | PR | PD | PR |
| Cancer status at latest follow-up (months from rechallenge) | Death caused by cancer progression | Maintained CR (32 months) | Maintained PR (25 months) | Death caused by cancer progression | Maintained PR (6 months) | Death caused by cancer progression | Maintained PR (17 months) |
*Prednisone equivalent doses.
CR, complete response; ICI, immune-checkpoint inhibitor; irAE, immune-related adverse event; PD, progression disease; PR, partial response.